QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
NYSE:IQV

IQVIA - IQV Stock Forecast, Price & News

$248.26
+2.45 (+1.00%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$244.27
$249.11
50-Day Range
$196.45
$245.81
52-Week Range
$194.67
$285.61
Volume
959,482 shs
Average Volume
1.12 million shs
Market Capitalization
$46.30 billion
P/E Ratio
41.45
Dividend Yield
N/A
Price Target
$274.44

IQVIA MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.94 Rating Score
Upside/​Downside
10.5% Upside
$274.44 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.69
Upright™ Environmental Score
News Sentiment
0.33mentions of IQVIA in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
13.01%
From $9.38 to $10.60 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Business Services Sector

64th out of 332 stocks

Commercial Physical Research Industry

5th out of 17 stocks

IQV stock logo

About IQVIA (NYSE:IQV) Stock

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

IQVIA Price Performance

Shares of IQV traded up $0.46 during midday trading on Monday, reaching $246.27. The stock had a trading volume of 9,451 shares, compared to its average volume of 1,109,420. The company's 50-day moving average is $219.11 and its 200 day moving average is $223.45. IQVIA has a 12-month low of $194.67 and a 12-month high of $285.61. The company has a current ratio of 0.96, a quick ratio of 0.96 and a debt-to-equity ratio of 2.36. The company has a market capitalization of $45.93 billion, a price-to-earnings ratio of 41.12, a price-to-earnings-growth ratio of 2.25 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Rating) last posted its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.22 by $0.22. IQVIA had a return on equity of 30.21% and a net margin of 8.21%. The firm had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.49 billion. During the same period in the prior year, the business earned $1.94 EPS. The company's revenue for the quarter was up 3.0% compared to the same quarter last year. On average, equities analysts predict that IQVIA will post 9.38 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on IQV. Evercore ISI raised their target price on IQVIA from $265.00 to $275.00 in a research report on Friday, July 22nd. Guggenheim raised their target price on IQVIA to $246.00 in a research report on Friday, July 22nd. Wells Fargo & Company downgraded IQVIA from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $290.00 to $235.00 in a research report on Monday, April 25th. Piper Sandler raised IQVIA from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $231.00 to $255.00 in a research report on Thursday, April 28th. Finally, Robert W. Baird boosted their price objective on IQVIA from $260.00 to $265.00 in a research note on Friday, July 22nd. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $274.44.

Receive IQV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.

IQV Stock News Headlines

Most profitable less than $5 stock in the world?
This virtually unknown stock trades under a secret name, brings in more cash than IBM, Facebook and Tesla, and trades for just under $5. Find out why in this "leaked" footage from a former Wall Street money manager. pixel
IQVIA (NYSE:IQV) Stock Rating Upgraded by StockNews.com
Most profitable less than $5 stock in the world?
This virtually unknown stock trades under a secret name, brings in more cash than IBM, Facebook and Tesla, and trades for just under $5. Find out why in this "leaked" footage from a former Wall Street money manager. pixel
Guggenheim Boosts IQVIA (NYSE:IQV) Price Target to $246.00
Barclays Boosts IQVIA (NYSE:IQV) Price Target to $255.00
IQVIA (NYSE:IQV) Shares Gap Up on Strong Earnings
IQVIA: Q2 Earnings Snapshot - Greenwich Time
IQVIA Reports Second-Quarter 2022 Results
See More Headlines
Receive IQV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.

IQV Company Calendar

Last Earnings
7/21/2022
Today
8/15/2022
Next Earnings (Estimated)
10/20/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Fax
N/A
Employees
79,000
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$274.44
High Stock Price Forecast
$320.00
Low Stock Price Forecast
$235.00
Forecasted Upside/Downside
+10.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
16 Analysts

Profitability

Net Income
$966 million
Pretax Margin
9.74%

Debt

Sales & Book Value

Annual Sales
$13.87 billion
Cash Flow
$15.36 per share
Book Value
$31.63 per share

Miscellaneous

Free Float
184,083,000
Market Cap
$46.30 billion
Optionable
Optionable
Beta
1.32

Social Links


Key Executives

  • Mr. Ari Bousbib (Age 61)
    Chairman, Pres & CEO
    Comp: $9.55M
  • Mr. Ronald E. Bruehlman (Age 61)
    Exec. VP & CFO
    Comp: $2.67M
  • Mr. Kevin C. Knightly (Age 61)
    Pres of Technology & Commercial Solutions
    Comp: $1.45M
  • Mr. Eric M. Sherbet (Age 58)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $1.37M
  • Mr. Emmanuel N. Korakis (Age 48)
    Sr. VP, Corp. Controller, Chief Accounting Officer & Treasurer
  • Dr. Jeffrey A. Spaeder
    Sr. VP, Global Chief Medical & Scientific Officer
  • Mr. Alejandro Martinez
    Chief Information Officer
  • Andrew Markwick
    Sr. VP of Investor Relations
  • Mr. Nicholas Childs
    Sr. VP, Investor Relations & Corp. Communications
  • Ms. Trudy Stein
    Chief HR Officer & Exec. VP













IQV Stock - Frequently Asked Questions

Should I buy or sell IQVIA stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IQV shares.
View IQV analyst ratings
or view top-rated stocks.

What is IQVIA's stock price forecast for 2022?

16 equities research analysts have issued 12-month target prices for IQVIA's shares. Their IQV share price forecasts range from $235.00 to $320.00. On average, they anticipate the company's share price to reach $274.44 in the next year. This suggests a possible upside of 10.5% from the stock's current price.
View analysts price targets for IQV
or view top-rated stocks among Wall Street analysts.

How have IQV shares performed in 2022?

IQVIA's stock was trading at $282.14 at the start of the year. Since then, IQV stock has decreased by 12.0% and is now trading at $248.26.
View the best growth stocks for 2022 here
.

Are investors shorting IQVIA?

IQVIA saw a decrease in short interest in July. As of July 31st, there was short interest totaling 1,670,000 shares, a decrease of 16.1% from the July 15th total of 1,990,000 shares. Based on an average trading volume of 1,050,000 shares, the short-interest ratio is currently 1.6 days. Approximately 0.9% of the shares of the stock are short sold.
View IQVIA's Short Interest
.

When is IQVIA's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 20th 2022.
View our IQV earnings forecast
.

How were IQVIA's earnings last quarter?

IQVIA Holdings Inc. (NYSE:IQV) issued its quarterly earnings results on Thursday, July, 21st. The medical research company reported $2.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.22. The medical research company earned $3.54 billion during the quarter, compared to analysts' expectations of $3.49 billion. IQVIA had a trailing twelve-month return on equity of 30.21% and a net margin of 8.21%. The business's quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.94 EPS.
Read the conference call transcript
.

What guidance has IQVIA issued on next quarter's earnings?

IQVIA issued an update on its third quarter 2022 earnings guidance on Friday, July, 29th. The company provided earnings per share (EPS) guidance of $2.34-$2.42 for the period, compared to the consensus EPS estimate of $2.48. The company issued revenue guidance of $3.52 billion-$3.56 billion, compared to the consensus revenue estimate of $3.61 billion.

What is Ari Bousbib's approval rating as IQVIA's CEO?

1,545 employees have rated IQVIA Chief Executive Officer Ari Bousbib on Glassdoor.com. Ari Bousbib has an approval rating of 84% among the company's employees.

What other stocks do shareholders of IQVIA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IQVIA investors own include CA (CA), BlackRock (BLK), NVIDIA (NVDA), Micron Technology (MU), Endologix (ELGX), Chipotle Mexican Grill (CMG), Alibaba Group (BABA), PayPal (PYPL), Salesforce (CRM) and Accenture (ACN).

What is IQVIA's stock symbol?

IQVIA trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Who are IQVIA's major shareholders?

IQVIA's stock is owned by a variety of institutional and retail investors. Top institutional investors include Bishop Rock Capital L.P. (2.17%), Lazard Asset Management LLC (1.56%), FMR LLC (1.10%), Northern Trust Corp (1.04%), Cantillon Capital Management LLC (0.84%) and Loomis Sayles & Co. L P (0.73%). Insiders that own company stock include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and Ronald E Bruehlman.
View institutional ownership trends
.

How do I buy shares of IQVIA?

Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IQVIA's stock price today?

One share of IQV stock can currently be purchased for approximately $248.26.

How much money does IQVIA make?

IQVIA (NYSE:IQV) has a market capitalization of $46.30 billion and generates $13.87 billion in revenue each year. The medical research company earns $966 million in net income (profit) each year or $5.99 on an earnings per share basis.

How many employees does IQVIA have?

The company employs 79,000 workers across the globe.

Does IQVIA have any subsidiaries?
The following companies are subsidiares of IQVIA: 159 Solutions LLC, 159 Technology Solutions Private Ltd, AECIO IT Solutions India Private Ltd., ALIMED Egeszsegugyi Szolgaltato Kft., Advanced Health Media LLC, Advanced Health Media Services Ltd., Aileron Solutions, Albatross Financial Solutions Limited, Allcare Plus Pharmacy LLC, Aposphäre GmbH, Appature Inc., Ardentia International Limited, Ascott Sales Integration Pty Ltd, Asesorias IQVIA Solutions Chile Limitada, Asserta Centroamerica Medicion de Mercados S.A., Avacare Clinical Research Network (Shanghai) Co. Ltd., BUZZEOPDMA LLC, Battaerd Mansley (Proprietary) Limited, Battaerd Mansley Pty. Ltd., Benefit Holding Inc., Biofortis LLC, Branch of IQVIA RDS GesmbH in Novosibirsk, Branch of IQVIA RDS GesmbH in St. Petersburg, CDS - Centre de Service SAS, CFS Clinical UK Limited, CRM Health Korea Ltd., CSD Health Korea Ltd., CT Clinical Portugal Unipessoal Lda, CT Clinical Services Eood, CT Consulting Inc., Cambridge Pharma Consultancy Inc., Cambridge Pharma Consultancy Limited, Cegedim Venezuela C.A., Cenduit (India) Services Private Company Limited, Cenduit GmbH, Cenduit Holdings LLC, Cenduit LLC, Cenduit LLC Shanghai Rep. Office, Cenduit Limited, Cenduit Mauritius Holdings Company, Centrix Innovations (Pty) Ltd., ClinTec Austria GmbH, ClinTec CRO Services (India) Private Limited, ClinTec Gesellschaft fur Klinische Entwicklung GmbH, ClinTec International (Pty) Ltd., ClinTec International (Pty) Ltd. (Malawi branch), ClinTec International (Thailand) Limited, ClinTec International AG, ClinTec International Belgium BV, ClinTec International Bulgaria OOD, ClinTec International Co. Ltd., ClinTec International Denmark ApS, ClinTec International FZ-LLC, ClinTec International Hong Kong Limited, ClinTec International Hungary Kft, ClinTec International Italy S.r.l., ClinTec International LLC, ClinTec International Limited, ClinTec International Ltd (Netherlands Branch), ClinTec International Ltd UK Filial Sverige, ClinTec International Ltd., ClinTec International Norway AS, ClinTec International Off-Shore S.A.L., ClinTec International Pte Ltd., ClinTec International Pty Ltd, ClinTec International RUS LLC, ClinTec International Romania S.R.L., ClinTec International S.à r.l., ClinTec International SL, ClinTec International Services Inc., ClinTec International d.o.o. za trgov inuisludge, ClinTec International doo, ClinTec International s.r.o., ClinTec International sp. z.o.o., ClinTec Luxembourg S.A., ClinTec Turkey Medikal ve Farmasotik Hizmetler Ticaret Limited Sirketi, ClinTech Ireland International Research Limited, Clinical Financial Services LLC, Clinical Insourcing Solutions Limited, Clinical Insourcing Solutions S. de R.L. de C.V., Clinical Lab Minority Shareholder Limited, Clintec International Inc., Clintec International Pharmaceutical Services Ltd, Compliant Community Projects (Pty) Ltd., CoreZetta Co Ltd., Data Niche Associates Inc., Dataline Software Limited, Datandina Ecuador S.A., Datec Industria e Comercio Distribudora Grafica e Mala Direta Ltda., Dimensions Healthcare Company Ltd, Dimensions Healthcare LLC, Dimensions Healthcare LLC (Dubai Branch), DrugDev, DrugDev Inc., DrugDev Limited, EA Institute L.L.C., EPID Research Oy, EPID Research Sweden, EPS Research Limited, EPS Software Limited, Enterprise Associates L.L.C., Epernicus LLC, Excel Life Sciences Inc., Excel Life Sciences Pvt Ltd India, Forcea NV, Foresight IT Solutions and Consulting India Private Limited, GCE Clin Solutions Limited, GCE Global Solutions LLC, GCE Solutions GmbH, GCE Solutions International LLC, GCE Solutions Proprietary Limited, GCE Solutions S. de R.L. de C.V., Global Crown Investment Limited, Grace Data Corp., HighPoint Solutions LLC, Highpoint Solutions LLC (Geneva Branch), Hospital Marketing Services Ltd., Hotel Lot C-8B LLC, IMS (UK) Pension Plan Trustee Company Limited, IMS AB, IMS Government Solutions Inc., IMS HEALTH GROUP LIMITED, IMS HEALTH KOREA LTD., IMS Health (Australia) Partnership, IMS Health Analytics Services Private Limited, IMS Health Information Solutions Australia Pty. Ltd, IMS Health Information Solutions India Private Ltd., IMS Health Networks Limited, IMS Health Paraguay SRL, IMS Health Surveys Limited, IMS Health Uruguay S.A., IMS Health de Venezuela C.A., IMS Hospital Group Limited, IMS Information Solutions Medical Research Limited, IMS Information Solutions UK Ltd., IMS International (Proprietary) Limited, IMS Meridian Limited, IMS Meridian Research Limited, IMS SOFTWARE SERVICES LTD., IMS Technology Solutions UK Limited, INCARNUS MALAYSIA SDN BHD, IPP Informacion Promocional y Publicitaria S.A. de C.V., IQVIA (Thailand) Co. Ltd., IQVIA AB, IQVIA AG, IQVIA AG (Basal Branch), IQVIA AG (Dubai Branch), IQVIA AG (Mexico Branch), IQVIA AG (Representative Office - Algeria), IQVIA AG (Representative Office - Dubai), IQVIA AG (Representative Office - Jordan), IQVIA AG (Representative Office - Lebanon), IQVIA AG (Representative Office - Serbia), IQVIA AG (Rotkreuz Branch), IQVIA AG (UK Branch), IQVIA Adriatic d.o.o. za Konzalting, IQVIA Asia Pacific Commercial Holdings LLC, IQVIA Beteiligungsgesellschaft mbH, IQVIA BioSciences Holdings LLC, IQVIA Biotech LLC, IQVIA Biotech Ltd., IQVIA CHINAMETRIK INC., IQVIA COMMERCIAL FINANCE INC., IQVIA COMMERCIAL INDIA HOLDINGS CORP., IQVIA COMMERCIAL SERVICES LLC, IQVIA COMMERCIAL TRADING CORP., IQVIA CSMS GmbH, IQVIA CSMS US Inc., IQVIA Clinical AB, IQVIA Clinical Filial af IQVIA Clinical AB, IQVIA Commercial Consulting Sp. z.o.o., IQVIA Commercial Deutschland GmbH, IQVIA Commercial GmbH & Co. OHG, IQVIA Commercial I LLC, IQVIA Commercial Software GmbH, IQVIA Commercial Sp. z.o.o., IQVIA Consulting Solutions BV, IQVIA Consulting and Information Services India Private Limited, IQVIA FZ-LLC, IQVIA Finance Ireland Designated Activity Company, IQVIA GOVERNMENT SOLUTIONS INC., IQVIA Healthcare (QFC Branch), IQVIA Hellas Technology Solutions Single Member S.A., IQVIA Holdings (UK) Ltd., IQVIA Holdings France SAS, IQVIA IES Brasil Ltda., IQVIA IES Denmark ApS, IQVIA IES Europe Limited, IQVIA IES European Holdings, IQVIA IES Italia S.r.l., IQVIA IES OY, IQVIA IES Overseas Holdings Limited, IQVIA IES Portugal Unipessoal LDA, IQVIA IES Puerto Rico Inc., IQVIA IES South Africa (Pty) Limited, IQVIA IES UK Limited, IQVIA II Technology Solutions Portugal Unipessoal LDA, IQVIA INC., IQVIA INFORMATION MEDICAL STATISTICS (ISRAEL) LTD., IQVIA Inc. (Thailand Branch), IQVIA Information S.A., IQVIA Information Solutions (China) Co. Ltd., IQVIA Information Solutions GmbH, IQVIA Integrated Services NL, IQVIA Investment Holdings Limited, IQVIA Korea Co. Ltd., IQVIA LTD., IQVIA Lebanon S.a.r.l., IQVIA Market Intelligence LLC, IQVIA Marktforschung GmbH, IQVIA Maroc S.à r.l., IQVIA MedTech Inc., IQVIA MedTech NV, IQVIA Medical Communications & Consulting Inc., IQVIA Medical Development (Dalian) Co. Ltd., IQVIA Medical Education Inc., IQVIA Medical Radar AB, IQVIA Operations France SAS, IQVIA PHARMA Inc., IQVIA Partners AS, IQVIA Pharma Services Corp., IQVIA Pharmaceutical Marketing Services Ltd., IQVIA Phase One Services LLC, IQVIA RDS (India) Private Ltd., IQVIA RDS (Pty.) Limited, IQVIA RDS (Shanghai) Co. Ltd., IQVIA RDS AG, IQVIA RDS Argentina S.R.L., IQVIA RDS Asia Inc., IQVIA RDS Austria GmbH, IQVIA RDS BT Inc., IQVIA RDS Brasil Ltda., IQVIA RDS Bulgaria EOOD, IQVIA RDS Canada ULC, IQVIA RDS Chile, IQVIA RDS Clindata (Pty.) Ltd., IQVIA RDS Clindepharm (Pty.) Ltd., IQVIA RDS Colombia S.A.S., IQVIA RDS Costa Rica S.A., IQVIA RDS Czech Republic s.r.o., IQVIA RDS ESTONIA OU, IQVIA RDS East Asia Pte. Ltd., IQVIA RDS Eastern Holdings GmbH, IQVIA RDS Egypt LLC, IQVIA RDS Finland OY, IQVIA RDS France SAS, IQVIA RDS Funding LLC, IQVIA RDS GesmbH, IQVIA RDS GmbH, IQVIA RDS Guatemala S.A., IQVIA RDS Hellas Single Member S.A., IQVIA RDS Holdings, IQVIA RDS Hong Kong Limited, IQVIA RDS Hungary Pharmaceutical Development and Consulting Limited Liability Company, IQVIA RDS ISRAEL LTD., IQVIA RDS Inc., IQVIA RDS Ireland (Finance) Ltd., IQVIA RDS Ireland Ltd., IQVIA RDS Italy S.r.l., IQVIA RDS Latin America LLC, IQVIA RDS Latin America LLC (Argentina Branch), IQVIA RDS Latvia SIA, IQVIA RDS Malaysia Sdn. Bhd., IQVIA RDS Netherlands B.V., IQVIA RDS Norway, IQVIA RDS Panama Inc., IQVIA RDS Peru S.r.l., IQVIA RDS Philippines Inc., IQVIA RDS Poland Sp. Zoo, IQVIA RDS Pty. Limited, IQVIA RDS Pty. Ltd., IQVIA RDS Slovakia s.r.o., IQVIA RDS South Africa (Pty.) Ltd., IQVIA RDS Spain S.L., IQVIA RDS Spain S.L. - Representação Permanente em Portugal, IQVIA RDS Switzerland S.à r.l., IQVIA RDS Taiwan Ltd., IQVIA RDS UAB, IQVIA RDS UK Holdings Ltd., IQVIA RDS Ukraine, IQVIA RDS Vietnam LLC, IQVIA RDS and Integrated Services Belgium NV, IQVIA RDS d.o.o. Beograd, IQVIA Research and Development Solutions Saudi Arabia Limited, IQVIA Romania S.R.L., IQVIA SOLUTIONS CANADA INC, IQVIA SOLUTIONS JAPAN K.K., IQVIA Services Japan K.K., IQVIA Solutions (NZ) Limited, IQVIA Solutions (Pty.) Ltd., IQVIA Solutions Argentina S.A., IQVIA Solutions Asia Pte. Ltd, IQVIA Solutions Australia Holdings Pty. Ltd., IQVIA Solutions Australia Pty. Ltd., IQVIA Solutions B.V., IQVIA Solutions Bangladesh Limited, IQVIA Solutions Belgium BV, IQVIA Solutions Bolivia S.R.L., IQVIA Solutions Bulgaria EOOD, IQVIA Solutions Colombia S.A., IQVIA Solutions Consulting Myanmar Company Limited, IQVIA Solutions Denmark AS, IQVIA Solutions Egypt Ltd., IQVIA Solutions Enterprise Management Consulting (Shanghai) Co. Ltd (Beijing Branch), IQVIA Solutions Enterprise Management Consulting (Shanghai) Co. Ltd., IQVIA Solutions Finance B.V., IQVIA Solutions Finance UK I Ltd., IQVIA Solutions Finance UK II Ltd., IQVIA Solutions Finance UK III Ltd., IQVIA Solutions Finance UK V Ltd., IQVIA Solutions Finland OY, IQVIA Solutions Global Holdings UK Ltd., IQVIA Solutions HQ Ltd., IQVIA Solutions Holdings (Pty.) Ltd., IQVIA Solutions Hong Kong Limited, IQVIA Solutions Ireland Limited, IQVIA Solutions Italy S.r.l., IQVIA Solutions Kazakhstan LLC, IQVIA Solutions LLC, IQVIA Solutions Lanka (Private) Limited, IQVIA Solutions Malaysia Sdn. Bhd., IQVIA Solutions Norway AS, IQVIA Solutions Operations Center Philippines Inc., IQVIA Solutions Pakistan (Private) Limited, IQVIA Solutions Pharmaceutical SRL, IQVIA Solutions Philippines Inc., IQVIA Solutions Portugal Lda, IQVIA Solutions Puerto Rico Inc., IQVIA Solutions Regional Pte. Ltd., IQVIA Solutions Republica Dominicana S.R.L., IQVIA Solutions Saudi Arabia Limited, IQVIA Solutions Services Ltd., IQVIA Solutions Sweden AB, IQVIA Solutions Tunisia S.à r.l., IQVIA Solutions UK Investments Ltd., IQVIA Solutions UK Limited, IQVIA Solutions a.s., IQVIA Solutions del Peru S.A., IQVIA Solutions do Brasil Ltda., IQVIA Solutions s.r.o., IQVIA Soluções de Tecnologia do Brasil Ltda, IQVIA Staff Services Sp.A., IQVIA TRANSPORTATION SERVICES CORP., IQVIA Technology Services Ltd., IQVIA Technology Solutions (China) Co. Ltd., IQVIA Technology Solutions Colombia Ltda., IQVIA Technology Solutions Egypt LLC, IQVIA Technology Solutions Finland OY, IQVIA Technology Solutions Poland SP. z.o.o, IQVIA Technology Solutions Romania Srl, IQVIA Technology Solutions S.R.O. (Bulgaria Branch), IQVIA Technology Solutions Ukraine LLC, IQVIA Technology Solutions s.r.o., IQVIA Technology Tunisia S.à r.l., IQVIA Tibbi Istatistik Ticaret ve Musavirlik Ltd. Sirketi, IQVIA Trading Management Inc., IQVIA World Publications Ltd., IQVIA Zagreb d.o.o., Iasist Holdco Limited, Iasist Portugal Consultadoria na Área de Saúde Unipessoal Lda, Iasist SAU Agencia en Chile, Iasist Sociedad Anonima Unipersonal, Impact RX Data Management (Pty) Ltd., Infocus Health Limited, Infopharm Ltd., Innovex Holdings I LLC, Innovex Merger Corp., Innovex Saglik Urunleri Pazarlame ve Hizmet Danismanlik Anonim Sirketi, Intercontinental Medical Statistics International Ltd., Intercontinental Medical Statistics Kenya Ltd., Interface Clinical Services Ltd., Interstatistik AG, Iqvia Solutions Taiwan Ltd., Jäger Health Gmbh, Kun Tai Medical Development Hong Kong Limited, Kun Tuo Medical Research & Development (Beijing) Co. Ltd., Laboratorio Commuq Pharma SLU, Linguamatics, Linguamatics Limited, Linguamatics Solutions Limited, M&H Informatics (BD) LTD., Mecurial Insights Holding Pty. Ltd., Mecurial Insights Pty. Ltd., Med-Vantage Inc., Meddata Group LLC, MedicSense Ltd., Medineos S.r.l., Mercados Y Analisis S.A., Meridian Research Vietnam Ltd., Novasyte LLC, Novella Clinical LLC, Novex Pharma Laboratorio S.L., Novex Pharma Limited, Nuevo Health Pty Ltd, Operaciones Centralizadas Latinoamericana Limitada, Optimum Contact Limited, Outcome Sciences LLC, PR Editions S.A.S., PT IQVIA RDS Indonesia, PT IQVIA Solutions Indonesia, Penderwood Limited, PharmARC Consulting Services GmbH, PharmARC Inc., Pharma Deals Limited, Pharma Strategy Group Limited, Pharmadata s.r.o., Pharmaforce S.A. de C.V., Polaris Management Partners LLC, Polaris Solutions LLC, Polaris Solutions Ltd., Privacy Analytics Inc., Professional Pharmaceutical Marketing Services (Pty.) Ltd., Prometheus Research LLC, Public Relations Algeria, Q Squared Solutions (Beijing) Co. Ltd., Q Squared Solutions (India) Private Limited, Q Squared Solutions (Quest) LLC, Q Squared Solutions (Quest) Limited, Q Squared Solutions (Shanghai) Co. Ltd., Q Squared Solutions B.V., Q Squared Solutions BioSciences LLC, Q Squared Solutions China (Quest) Limited, Q Squared Solutions China Limited, Q Squared Solutions Expression Analysis LLC, Q Squared Solutions Holdings B.V., Q Squared Solutions Holdings LLC, Q Squared Solutions Holdings Limited, Q Squared Solutions KK, Q Squared Solutions LLC, Q Squared Solutions Limited, Q Squared Solutions Proprietary Limited, Q Squared Solutions Pte. Ltd., Q Squared Solutions S.A., Q2 Solutions, QH Research Limited, QIMS Pharma Services SA DE CV, Qcare Site Services Inc., Quality Health Limited, Quintiles Benin Ltd., Quintiles Clinical and Commercial Nigeria Limited, Quintiles Commercial Laboratorio S.L.U., Quintiles Commercial Rus LLC, Quintiles East Africa Limited, Quintiles Finance Uruguay S.r.L., Quintiles IMS Japan GK, Quintiles Lanka (Private) Limited, Quintiles Mauritius Holdings, Quintiles Medical Development (Shanghai) Co. Ltd., Quintiles Mexico S. de R.L. de C.V., Quintiles New Zealand, Quintiles Phase One Clinical Trials India Private Limited, Quintiles RDS Latin America LLC, Quintiles Site Services S.A., Quintiles West Africa Limited, RX India LLC, Radar Acquisition Blocker Inc., Redsite Limited, Representative Office of IQVIA RDS GesmbH in Moscow, STI Technologies Limited, Schwarzeck Verlag GmbH, Secureconsent LLC, Shanghai IMS Market Research Co. Ltd., Smart I.T. Systems BV, Source Informatics Limited, Spartan Leasing Corporation, StatFin Estonia, Statfinn Oy, Targeted Molecular Diagnostics LLC, Tarius A/S, Temas Srl - Società Unipersonale, TforG Support NV, The Amundsen Group Inc., Themis Limited, UAB IQVIA Commercial, VCG&A Inc., VCG-BIO Inc., Valuecentric Global Services Gmbh, Valuecentric Privacy Solutions LLC, Valuemedics Research LLC, Vivacity Health Pty. Ltd., genae Germany Gmbh, genae International Ag, and iGuard Inc..
Read More
When was IQVIA founded?

IQVIA was founded in 2016.

How can I contact IQVIA?

IQVIA's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The official website for the company is www.iqvia.com. The medical research company can be reached via phone at (919) 998-2000 or via email at ir@iqvia.com.

This page (NYSE:IQV) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.